Repligen Corporation (NASDAQ:RGEN) Shares Acquired by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. increased its position in shares of Repligen Corporation (NASDAQ:RGEN) by 4.4% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,632 shares of the biotechnology company’s stock after purchasing an additional 152 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Repligen were worth $462,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of RGEN. Raiffeisen Bank International AG acquired a new position in shares of Repligen during the 4th quarter worth $29,000. Itau Unibanco Holding S.A. purchased a new position in Repligen during the 4th quarter valued at about $40,000. Signaturefd LLC raised its position in Repligen by 65.3% during the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 128 shares during the last quarter. Center for Financial Planning Inc. raised its position in Repligen by 110.3% during the first quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 193 shares during the last quarter. Finally, UMB Bank n.a. lifted its holdings in shares of Repligen by 99.4% in the first quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 332 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Repligen

In related news, Director Martin D. Madaus acquired 1,800 shares of the stock in a transaction dated Friday, August 8th. The stock was bought at an average cost of $112.13 per share, with a total value of $201,834.00. Following the purchase, the director directly owned 1,800 shares of the company’s stock, valued at approximately $201,834. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.20% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on RGEN shares. Stephens raised shares of Repligen to an “overweight” rating and set a $160.00 price objective for the company in a research note on Tuesday, July 22nd. Canaccord Genuity Group decreased their price objective on Repligen from $170.00 to $150.00 and set a “hold” rating on the stock in a research note on Wednesday, April 16th. Wolfe Research upgraded Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 price objective for the company in a research report on Tuesday, April 29th. HC Wainwright restated a “buy” rating and issued a $180.00 target price on shares of Repligen in a report on Monday, May 5th. Finally, Barclays began coverage on shares of Repligen in a research note on Tuesday, June 24th. They set an “overweight” rating and a $150.00 price target on the stock. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $169.45.

Repligen Stock Up 4.7%

Shares of NASDAQ:RGEN opened at $127.15 on Thursday. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26. The firm has a market cap of $7.15 billion, a price-to-earnings ratio of -508.58, a PEG ratio of 2.23 and a beta of 1.05. The stock’s 50-day moving average price is $122.58 and its two-hundred day moving average price is $133.62. Repligen Corporation has a 12-month low of $102.96 and a 12-month high of $182.52.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%. The company had revenue of $182.37 million during the quarter, compared to analyst estimates of $174.62 million. During the same period in the prior year, the business posted $0.40 earnings per share. Repligen’s revenue was up 14.8% on a year-over-year basis. On average, research analysts forecast that Repligen Corporation will post 1.72 EPS for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.